Human Pathology
Volume 41, Issue 5 , Pages 716-723 , May 2010

Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma

  • Liang Cheng, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Shaobo Zhang, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • ,
  • Aleksander Talerman, MD

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • ,
  • Lawrence M. Roth, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Received 10 July 2009 ,Revised 21 October 2009 ,Accepted 23 October 2009.

References 

  1. Roth LM, Talerman A. Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol. 2006;25:305–320
  2. Clement PB, Young RH. Atlas of gynecological pathology. 2nd ed.. Philadelphia: Sauders/Elsevier; 2008;
  3. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25:2938–2943
  4. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008;34:427–441
  5. In:  Tavassoli FA,  Devilee P editor. World Health Organization Classification of Tumours: pathology and genetics of tumours of the female genital tract. Lyon: IARC Press; 2003;p. 163–179
  6. Cheng L, Sung MT, Cossu-Rocca P, et al. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol. 2007;211:1–9
  7. Sung MT, Jones TD, Beck SD, Foster RS, Cheng L. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum Pathol. 2006;37:662–667
  8. Abbosh PH, Zhang S, Maclennan GT, et al. Germ cell origin of testicular carcinoid tumors. Clin Cancer Res. 2008;14:1393–1396
  9. Cheng L, Zhang S, Wang M, et al. Molecular genetic evidence supporting the neoplastic nature of stromal cells in “fibrosis” after chemotherapy for testicular germ cell tumours. J Pathol. 2007;213:65–71
  10. Cheng L, Zhang D. Molecular genetic pathology. New York: Humana Press/Springer; 2008;
  11. Cheng L, Zhang S, MacLennan GT, et al. Interphase fluorescence in situ hybridization analysis of chromosome 12p abnormalities is useful to distinguish epidermoid cyst of the testis from pure mature teratoma. Clin Cancer Res. 2006;12:5668–5772
  12. Sung MT, Maclennan GT, Lopez-Beltran A, Zhang S, Montironi R, Cheng L. Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. Am J Surg Pathol. 2008;32:146–155
  13. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32:600–607
  14. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2004;101:2006–2010
  15. Cheng L, Thomas A, Roth LM, Zheng WM, Michael H, Abdul-Karim FW. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28:1341–1346
  16. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63:2244–2250
  17. Teilum G. Special tumors of ovary and testis and related extragonadal lesons: comparative pathology and histological identification. 2nd ed.. Philadelphia: Lippincott; 1976;
  18. Jones TD, Ulbright TM, Eble JN, Cheng L. OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res. 2004;10:8544–8547
  19. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol. 2004;28:935–940
  20. Gopalan A, Dhall D, Olgac S, et al. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol. 2009;22:1066–1074
  21. Chang MC, Vargas SO, Hornick JL, Hirsch MS, Crum CP, Nucci MR. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int J Gynecol Pathol. 2009;28:347–355
  22. Ngan KW, Jung SM, Lee LY, Chuang WY, Yeh CJ, Hsieh YY. Immunohistochemical expression of OCT4 in primary central nervous system germ cell tumours. J Clin Neurosci. 2008;15:149–152
  23. Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol. 2005;24:39–55
  24. Latza U, Foss HD, Durkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol. 1995;146:463–471
  25. Leroy X, Augusto D, Leteurtre E, Gosselin B. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem. 2002;50:283–285
  26. Berney DM, Shamash J, Pieroni K, Oliver RT. Loss of CD30 expression in metastatic embryonal carcinoma: the effects of chemotherapy?. Histopathology. 2001;39:382–385
  27. de Jong J, Stoop H, Gillis AJ, et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol. 2008;215:21–30
  28. Boer B, Kopp J, Mallanna S, et al. Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic Acids Res. 2007;35:1773–1786
  29. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007;31:836–845
  30. Phi JH, Park SH, Paek SH, et al. Expression of Sox2 in mature and immature teratomas of central nervous system. Mod Pathol. 2007;20:742–748
  31. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591–1598
  32. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570–1575
  33. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129:899–906
  34. Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224–230
  35. Ota S, Hishinuma M, Yamauchi N, et al. Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 2006;449:308–314
  36. Sever M, Jones TD, Roth LM, et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol. 2005;18:1411–1416

PII: S0046-8177(09)00395-5

doi: 10.1016/j.humpath.2009.10.016

Human Pathology
Volume 41, Issue 5 , Pages 716-723 , May 2010

Article Tools

* Image Usage & Resolution